Hanmi Pharm. Co., Ltd.

Cheil Industries Inc.

Hanmi Science Co., Ltd.

Hanmi Holdings Co., Ltd.

Hammi Holdings Co., Ltd

Young-Kil Chang

Gha-Seung Park

Gwan-Sun Lee

Gwan Sun Lee

Jaeheon Lee

Chul-Hyun Park

Bok-Nam Jang

Jae-Heon Lee

Gyu-Cheol Lee

Jae-cheol Lee

Han Kyong Kim

Young Ho Moon

Se-Jong Kim

Cheol-Kyung Kim

Moonsub Lee

Ji Sook Kim

Cheol Kyung Kim

Moon Sub Lee

Sang Min Yun

Sang-Hyun Hong

Chul Hyun Park

Jin Hee Kim

Eun Jung Lim

Eun-Ju Park

Hong-Sun Kim

Dong Jin Hong

Weon Ki Yang

Hyo-Jeong Bang

Jaeho Yoo

Ji Eun Lee

Jung-Hyun Kim

Jae Chul Lee

Young-ho Moon

Dong Jun Kim

Nam-Du Kim

Kyung-Ik Lee

Byeong-do Lee

Jae Ho Yoo

Sung-Hee Ahn

Cheol Hyun Park

Jae-Ho Yang

Tae Jin Choi

Gha Seung Park

Moon-Sub Lee

Cheol Kyong Kim

Kyung Ik Lee

Yoon Ju Lee

Ji-Yeon Chang

Yong-Hoon An

Keum-Shin Jung

Chang-Ju Choi

Han-Kyong Kim

Hoe Chul Lee

Cheol-Kyong Kim

Yong-Hae Kweon

Jae-Chul Lee

Eun-ju Park

Cheol-Kyong Sinnamusil Sinmyeong Apt 634-1003 Kim

Gha-Seung Sinjeongmaeul 1-Danji 107-1003 Park

Jae-Chul Kyungwonyeonlip Ra-Dong 101 Lee

The present invention relates to a high-yield method for preparing highly pure (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone using a metal salt of (2S,3S,5R)-2-hexyl-3,5-dihydroxyhexadecanoic acid as an intermediate.

Method for preparing (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone and novel intermediate used therefor

The present invention relates to a novel, high-yield and low-cost method for preparing entecavir, [1-S-(1&#x3b1;,3&#x3b1;,4&#x3b2;)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one, an antiviral agent, and novel intermediates used therein.

Intermediate and process for preparing entecavir using same

Provided is a method of preparing a (6R)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydropyran-2-one, and a (5R)-2-hexyl-5-hydroxy-3-iminohexadecanoate derivative used in said method as an intermediate.

Method of preparing (6R)-3-hexyl-4-hydroxy-6-undecyl-5, 6-dihydropyran-2-one, and intermediate used in the method

The present invention relates to a method for preparing montelukast, an inhibitor against leukotrienes, and an intermediate used therein. According to the inventive method, high-purity montelukast or its sodium salt can be prepared in a high yield.

Method of preparing montelukast and intermediates used therein

The present invention relates to a method for preparing capecitabine and a method for preparing a &#x3b2;-anomer-rich trialkyl carbonate compound used therein, and a highly pure capecitabine can be efficiently prepared with a high yield by the method of the present invention using the &#x3b2;-anomer-rich trialkyl carbonate compound as an intermediate.

Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein

1-&#x3b1;-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative of formula (I) having the 3-hydroxy group protected with a biphenylcarbonyl group is a solid which can be easily purified by a simple procedure such as recrystallization, and therefore, it can be advantageously used as an intermediate in the preparation of gemcitabine in a large scale. Further, the 1-&#x3b1;-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative of formula (I) can be prepared with high stereoselectivity using the compound of formula (V) as an intermediate.

1-&#x3b1;-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereof

Provided is an improved method for stereoselectively preparing 2'-deoxy-2&#x2032;,2&#x2032;-difluorocytidine of formula (I), which includes reacting a 1-halo ribofuranose compound with a nucleobase of formula (IV) in a solvent to obtain a nucleo side of formula (II) with removal of a silyl halide ((alkyl)SiX (X=halide)); and deprotecting the nucleoside of formula (II) to obtain 2&#x2032;-deoxy-2&#x2032;,2&#x2032;-difluorocytidine of formula (I). 2&#x2032;-Deoxy-2&#x2032;,2&#x2032;-difluorocytidine of formula (I) is effective for treating various cancers such as non-small cell lung (NSCLC), pancreatic, bladder, breast or ovarian cancers. 

Method for the preparation of 2'-deoxy-2&#x2032;,2&#x2032;-difluorocytidine

3R-carboxylate enantiomer derivative of formula (III) can be prepared easily and selectively by the method of the present invention, and a highly pure D-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative can be prepared efficiently from the compound of formula (III) as an intermediate.

Method for the preparation of D-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative

Risperidone is prepared in a high yield by reacting 2,4-difluorophenyl(4-piperidinyl)methanone oxime hydrochloride and 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one in an aqueous alkali hydroxide solution having an alkali hydroxide concentration in the range of 20 to 40%.

Method for preparing risperidone

High purity cefdinir is prepared in a high yield by a process comprising the steps of: treating a crystalline salt of a cefdinir intermediate with a formic acid-sulfuric acid mixture or a formic acid-methanesulfonic acid mixture to obtain a crystalline salt of cefdinir and reacting the crystalline salt with a base in a solvent.

Crystalline acid salts of cefdinir and process for preparing cefdinir using same

A 3-(Z)-propenyl cephem compound is selectively prepared by reacting a phosphoranylidene cephem compound with acetaldehyde in the presence of a base in a solvent mixture comprising diethyl ether, formula (I), wherein R is a carboxyl protecting group; Ris hydrogen or RCHCO&#x2014;; and Ris ethyl, 2-thiophenyl, phenyl, p-hydroxyphenyl or phenoxy 

Process for the selective preparation of 3-(z) propenyl-cephem compound

This invention relates to a method for selectively preparing the 3-oxo-4-aza-5&#xa5;&#xe1;-androstane compound which is used as an intermediate of finasteride by heating 3-oxo-4-aza-5-androstene in a mixture of formic acid and an alkanediol in the presence of zinc.

Method for the selective preparation of 3-oxo-4-aza-5&#x3b1;-androstane compound

A method for preparing a 1-androstene derivative which comprises reacting a 2-iodo-androstane derivative with an oxidizing agent while maintaining the pH of the reaction mixture at a specific range gives the 1-androstene derivative with high purity and yield.

Method for the preparation of highly pure 1-androstene derivatives

A flameproof thermoplastic resin composition substantially free of phenolic resin, red phosphorous and silicone resin comprises (A) about 40-95 parts by weight of a rubber modified styrene-containing graft copolymer resin, (B) about 5-60 parts by weight of polyphenylene ether resin; (C) about 5-30 parts by weight of aromatic phosphoric acid ester per 100 part by weight of (A) and (B) wherein the styrene-containing copolymer chains in rubber modified styrene-containing resin (A) comprise

Flameproof styrene-containing graft resin compositions having a particular nitrile content distribution

The present invention relates to a pharmaceutical composition for treating or preventing obesity, comprising novel crystalline sibutramine methanesulfonate hemihydrate of formula (I). The crystalline sibutramine methanesulfonate hemihydrate according to the present invention has a much higher solubility in water, and enhanced stability under a high humidity/temperature condition, as compared with sibutramine hydrochloride monohydrate

Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate

Growing community of inventors

Seoul, South Korea

Young-Kil Chang